Recently published Non-muscle Invasive Bladder Cancer Market Insights report includes a comprehensive understanding of current treatment practices, non-muscle invasive bladder cancer emerging drugs, ...

Merck MRK announced that the European Commission has approved its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), and ...

The EC has approved MSD's Keytruda in combination with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer (MIBC).

Japanese drugmaker Astellas Pharma has won European Commission (EC) approval for Padcev (enfortumab vedotin) in combination ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv ...

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

Tiny algae-based robots guided by magnets could improve bladder cancer treatment by boosting delivery of chemotherapy drugs ...

Researchers at The University of Texas MD Anderson Cancer Center have developed a spatial map of muscle-invasive bladder ...

Discover the 3 Best-Performing Biotech IPO Stocks of 2024 CG Oncology (NASDAQ:CGON) Chief Executive Officer Arthur outlined ...

Bladder cancer is often mistaken for UTIs with a urologist outliningg a list of 'painless' symptoms you should never ignore.

Spatial analyses uncovered how different tumor regions interact with immune cells and respond to therapies, offering a new ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...